H.C. Wainwright lowered the firm’s price target on Cocrystal Pharma (COCP) to $6 from $7 and keeps a Buy rating on the shares. The firm says CDI-988 demonstrated “further promise” via activity against emergent norovirus variants. It cites anticipated equity dilution for the target cut.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCP:
- Cocrystal Pharma’s CDI-988 Featured at Military Symposium
- Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency
- Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza
- Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year
- Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988